

CITATION REPORT

List of articles citing

Reassessing Carbamazepine in the Treatment of Bipolar Disorder Clinical Implications of New Data

DOI: 10.1017/s1092852900023063
CNS Spectrums, 2005, 10, 1-2.

Source: <https://exaly.com/paper-pdf/38672024/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
187	The expert consensus guideline series. Treatment of behavioral emergencies 2005. 2005 , 11 Suppl 1, 5-108; quiz 110-2		154
186	Migraine with aura from pathophysiology to treatment: therapeutic strategies. 2005 , 26 Suppl 2, s104-7		6
185	A clinical overview of pseudobulbar affect. 2005 , 3 Suppl A, 4-8; quiz 16-7		14
184	Safety and tolerability of mood-stabilising anticonvulsants in the elderly. 2006 , 5, 401-16		12
183	C.02.02 Understanding the complexities of treatment informed by new research. 2006 , 16, S572-S573		
182	C.03.03 Monitoring patients to improve physical health and treatment outcome. 2006 , 16, S573-S574		
181	Effect of initial ziprasidone dose on length of therapy in schizophrenia. <i>Schizophrenia Research</i> , 2006 , 83, 285-92	3.6	20
180	Association of delusions and lack of cognitive flexibility with social anxiety in schizophrenia spectrum disorders. <i>Schizophrenia Research</i> , 2006 , 86, 147-53	3.6	22
179	Relief of depressive symptoms in an elderly patient with low back pain. 2006 , 9, 34-38		2
178	Treatment adherence among patients with schizophrenia treated with atypical and typical antipsychotics. <i>Psychiatry Research</i> , 2006 , 144, 177-89	9.9	30
177	Current animal models of obsessive compulsive disorder: a critical review. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2006 , 30, 374-88	5.5	130
176	Gender differences in the association between religious involvement and depression: the Cache County (Utah) study. 2006 , 61, P129-36		34
175	Insight and quality of life in schizophrenia: recent findings and treatment implications. <i>Current Opinion in Psychiatry</i> , 2006 , 19, 637-41	4.9	57
174	Treatment of aura: solving the puzzle. 2006 , 27 Suppl 2, S96-9		16
173	Duloxetine for neuropathic pain based on recent clinical trials. 2006 , 10, 199-204		11
172	Too much or too little pain: The dichotomy of pain sensitivity in psychotic versus other psychiatric disorders. 2006 , 4, 134-138		4
171	Probable association between ziprasidone and worsening hypertension. 2006 , 26, 1352-7		5

170	New-onset bipolar disorder in late life: a case of mistaken identity. 2006 , 163, 198-203		24
169	Ziprasidone in bipolar disorder. <i>Expert Opinion on Pharmacotherapy</i> , 2006 , 7, 1221-8	4	3
168	The use of antipsychotics in children and adolescents with bipolar disorders. <i>Expert Opinion on Pharmacotherapy</i> , 2007 , 8, 2673-87	4	7
167	Antipsychotic Medication Use in the Elderly Patient. 2007 , 20, 318-326		5
166	Bipolar switching after carbamazepine withdrawal. <i>Pharmacopsychiatry</i> , 2007 , 40, 86-7	2	0
165	Attention-Deficit/Hyperactivity Disorder. 2007 ,		
164	Involuntary emotional expression disorder: definition, diagnosis, and measurement scales. <i>CNS Spectrums</i> , 2007 , 12, 11-6	1.8	4
163	An independent meta-analysis using summary data for clinical response, remission, and discontinuation for any reason from the 6 pivotal phase III randomized clinical trials of duloxetine in major depressive disorder. <i>Journal of Clinical Psychopharmacology</i> , 2007 , 27, 219-21	1.7	5
162	N-acetyl cysteine in the treatment of grooming disorders. <i>Journal of Clinical Psychopharmacology</i> , 2007 , 27, 227-9	1.7	80
161	Time-dependent clearance decrements of fluvoxamine in depressed inpatients: a clinical evaluation. <i>Journal of Clinical Psychopharmacology</i> , 2007 , 27, 231-3	1.7	1
160	Factors affecting outcome in schizophrenia and their relevance for psychopharmacological treatment. <i>International Clinical Psychopharmacology</i> , 2007 , 22, 249-67	2.2	40
159	Comparison of ziprasidone and aripiprazole in acutely ill patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, 4-week study. <i>International Clinical Psychopharmacology</i> , 2007 , 22, 363-70	2.2	38
158	An open-label trial of aripiprazole augmentation for treatment-resistant generalized anxiety disorder. <i>Journal of Clinical Psychopharmacology</i> , 2007 , 27, 207-10	1.7	36
157	Changes in hippocampal volume in patients with post-traumatic stress disorder after sertraline treatment. <i>Journal of Clinical Psychopharmacology</i> , 2007 , 27, 233-5	1.7	29
156	Smoking cessation in schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2007 , 27, 239-40; author reply 240	1.7	1
155	Aripiprazole and neuroleptic malignant syndrome. <i>Journal of Clinical Psychopharmacology</i> , 2007 , 27, 212-47		8
154	Atypical antipsychotic drug-induced acute laryngeal dystonia: 2 case reports. <i>Journal of Clinical Psychopharmacology</i> , 2007 , 27, 206-7	1.7	17
153	Adjuvant levetiracetam in adolescent mania. <i>Journal of Clinical Psychopharmacology</i> , 2007 , 27, 215-6	1.7	7

152	Pancytopenia associated with the introduction of oxcarbazepine. <i>Journal of Clinical Psychopharmacology</i> , 2007 , 27, 217-8	1.7	10
151	Manic episode with psychotic symptoms associated with high dose of disulfiram: a case report. <i>Journal of Clinical Psychopharmacology</i> , 2007 , 27, 224-5	1.7	12
150	Reply to Comments by Dr Babbar. <i>Journal of Clinical Psychopharmacology</i> , 2007 , 27, 240	1.7	
149	Aripiprazole augmentation of tranylcypromine in treatment-resistant major depression. <i>Journal of Clinical Psychopharmacology</i> , 2007 , 27, 216-7	1.7	8
148	Worsening of obsessive-compulsive symptoms after treatment with aripiprazole. <i>Journal of Clinical Psychopharmacology</i> , 2007 , 27, 237-8	1.7	14
147	Exposure to nitrous oxide may be associated with high homocysteine plasma levels and a risk for clinical depression. <i>Journal of Clinical Psychopharmacology</i> , 2007 , 27, 238-9	1.7	2
146	Psychiatric aspects of pain. <i>Current Opinion in Psychiatry</i> , 2007 , 20, 42-6	4.9	63
145	Acute nocturnal akathisia induced by clozapine. <i>Journal of Clinical Psychopharmacology</i> , 2007 , 27, 205	1.7	4
144	A 6-month longitudinal study of early-onset tardive dyskinesia: association with olanzapine treatment and mild cognitive impairment in an elderly woman. <i>Journal of Clinical Psychopharmacology</i> , 2007 , 27, 210-2	1.7	4
143	Cognitive side effects of valproic acid-induced hyperammonemia in children with epilepsy. <i>Journal of Clinical Psychopharmacology</i> , 2007 , 27, 221-4	1.7	13
142	Escitalopram for compulsive buying disorder: a double-blind discontinuation study. <i>Journal of Clinical Psychopharmacology</i> , 2007 , 27, 225-7	1.7	87
141	Intramuscular aripiprazole in the control of agitation. 2007 , 13, 159-69		23
140	CÉtoacidose diabÉtique. 2007 , 4, 1-11		
139	Escitalopram-associated serotonin toxicity. <i>Journal of Clinical Psychopharmacology</i> , 2007 , 27, 229-30	1.7	5
138	Amenorrhea after sertraline introduction in an amisulpride-treated patient with undiagnosed polycystic ovary disease. <i>Journal of Clinical Psychopharmacology</i> , 2007 , 27, 235-7	1.7	1
137	Olanzapine-associated bilateral eyelid edema. <i>Journal of Clinical Psychopharmacology</i> , 2007 , 27, 214-5	1.7	10
136	EPS profiles: the atypical antipsychotics are not all the same. 2007 , 13, 13-24		103
135	Recognizing involuntary emotional expression disorder. 2007 , 39, 202-7		4

134	Gold nanoparticles modified indium tin oxide electrode for the simultaneous determination of dopamine and serotonin: Application in pharmaceutical formulations and biological fluids. <i>Talanta</i> , 2007 , 72, 976-83	6.2	200
133	Effectiveness, tolerability, and safety of ziprasidone in patients with schizophrenia or schizoaffective disorder: results of a multi-centre observational trial. 2007 , 22, 195-202		16
132	Therapeutic use of dextromethorphan: key learnings from treatment of pseudobulbar affect. 2007 , 259, 67-73		8
131	Perfil de los pacientes ingresados en UCI con cetoacidosis diabética. 2007 , 54, 255-258		2
130	It's nothing to laugh about: understanding disorders of emotional expression. 2007 , 22, 732-42		2
129	Augmentation strategies for treatment-resistant depression: a literature review. 2007 , 32, 415-28		77
128	Assessing the impact of pharmacologic intervention on the quality of life in diabetic peripheral neuropathic pain and fibromyalgia. 2007 , 8 Suppl 2, S33-42		10
127	Negative symptoms of schizophrenia: a problem that will not go away. <i>Acta Psychiatrica Scandinavica</i> , 2007 , 115, 4-11	6.5	121
126	Management of musculoskeletal pain. 2007 , 21, 153-66		77
125	Improving quality of care for mental illness in an uninsured, low-income primary care population. 2007 , 29, 302-9		5
124	Open-label aripiprazole in the treatment of acute bipolar depression: a prospective pilot trial. <i>Journal of Affective Disorders</i> , 2007 , 101, 275-81	6.6	43
123	PDE inhibitors in psychiatry--future options for dementia, depression and schizophrenia?. 2007 , 12, 870-8		80
122	QT prolongation and Torsades de Pointes following overdose of ziprasidone and amantadine. 2007 , 3, 178-81		28
121	Metabolic syndrome in bipolar disorder: a cross-sectional assessment of a Health Management Organization database. <i>Bipolar Disorders</i> , 2008 , 10, 607-16	3.8	97
120	Brain responses to verbal stimuli among multiple sclerosis patients with pseudobulbar affect. 2008 , 271, 137-47		28
119	Subjective and objective quality of life in schizophrenia. <i>Schizophrenia Research</i> , 2008 , 98, 201-8	3.6	159
118	Insulin resistance following continuous, chronic olanzapine treatment: an animal model. <i>Schizophrenia Research</i> , 2008 , 104, 23-30	3.6	44
117	[Factors related to the length of the corrected QT interval in patients treated with antipsychotics]. 2008 , 130, 446-9		1

116	Fluvoxamine as a sigma-1 receptor agonist improved cognitive impairments in a patient with schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2008 , 32, 1072-3	5.5	25
115	Ziprasidone in the treatment of affective disorders: a review. 2008 , 14, 278-86		20
114	Agitation treatment for pediatric emergency patients. 2008 , 47, 132-138		24
113	Polypharmacy with second-generation antipsychotics: a review of evidence. 2008 , 14, 345-67		42
112	Examining Children's Fears in the Aftermath of Hurricane Katrina. 2008 , 7, 253-275		6
111	Quality of life in older ages. 2008 , 85, 113-26		230
110	Treatment options for insomnia--pharmacodynamics of zolpidem extended-release to benefit next-day performance. 2008 , 120, 161-71		13
109	Response to emotional expressions in generalized social phobia and generalized anxiety disorder: evidence for separate disorders. 2008 , 165, 1193-202		220
108	Neurobehavioral sequelae of traumatic brain injury: evaluation and management. 2008 , 7, 3-10		124
107	Church attendance and new episodes of major depression in a community study of older adults: the Cache County Study. 2008 , 63, P129-37		31
106	Side effects of clozapine and some other psychoactive drugs. 2008 , 3, 115-22		37
105	The influence of 5-HTTLPR and STin2 polymorphisms in the serotonin transporter gene on treatment effect of selective serotonin reuptake inhibitors in depressive patients. 2008 , 18, 184-90		48
104	Assessment of clinical and metabolic status, and subjective well-being, in schizophrenic patients switched from typical and atypical antipsychotics to ziprasidone. <i>International Clinical Psychopharmacology</i> , 2008 , 23, 216-22	2.2	25
103	Insulin resistance and decreased glucose-stimulated insulin secretion after acute olanzapine administration. <i>Journal of Clinical Psychopharmacology</i> , 2008 , 28, 494-9	1.7	77
102	Transtorno da expressão emocional involuntária. 2008 , 35, 20-25		1
101	Ziprasidone in the treatment of mania in bipolar disorder. <i>Neuropsychiatric Disease and Treatment</i> , 2007 , 3, 823-34	3.1	1
100	Stimulus-reinforcement-based decision making and anxiety: impairment in generalized anxiety disorder (GAD) but not in generalized social phobia (GSP). 2009 , 39, 1153-61		22
99	Metabolic and Cardiac Side Effects of Second-generation Antipsychotics: What Every Clinician Should Know. 2009 , 22, 478-488		8

98	Reproductive and metabolic abnormalities associated with bipolar disorder and its treatment. 2009 , 17, 138-46		30
97	Conventional intramuscular sedatives versus ziprasidone for severe agitation in adolescents: case-control study. 2009 , 3, 9		20
96	A double-blind, placebo-controlled trial of rosiglitazone for clozapine-induced glucose metabolism impairment in patients with schizophrenia. <i>Acta Psychiatrica Scandinavica</i> , 2009 , 119, 457-65	6.5	33
95	Long-term haloperidol treatment (but not risperidone) enhances addiction-related behaviors in mice: role of dopamine D2 receptors. 2009 , 14, 283-93		24
94	The International Society for Bipolar Disorders (ISBD) consensus guidelines for the safety monitoring of bipolar disorder treatments. <i>Bipolar Disorders</i> , 2009 , 11, 559-95	3.8	125
93	The socio-economical burden of schizophrenia: a simulation of cost-offset of early intervention program in Italy. 2009 , 24, 11-6		21
92	Psychopharmacological neuroprotection in neurodegenerative disease: heuristic clinical applications. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2010 , 22, 130-54	2.7	13
91	A systematic, updated review on the antidepressant agomelatine focusing on its melatonergic modulation. 2010 , 8, 287-304		86
90	Coming to grips with complex disorders: genetic risk prediction in bipolar disorder using panels of genes identified through convergent functional genomics. 2010 , 153B, 850-77		41
89	A disposable amperometric sensor for rapid detection of serotonin in the blood and brain of the depressed mice based on Nafion membrane-coated colloidal gold screen-printed electrode. 2010 , 640, 1-7		38
88	Relationship of psychopathological symptoms and cognitive function to subjective quality of life in patients with chronic schizophrenia. 2010 , 64, 62-9		38
87	Metabolic dysfunction in women with bipolar disorder: the potential influence of family history of type 2 diabetes mellitus. <i>Bipolar Disorders</i> , 2010 , 12, 504-13	3.8	17
86	ARNTL (BMAL1) and NPAS2 gene variants contribute to fertility and seasonality. <i>PLoS ONE</i> , 2010 , 5, e100007	9.7	74
85	Safety of the electroconvulsive therapy-ziprasidone combination. <i>Journal of ECT</i> , 2010 , 26, 139-42	2	5
84	Pharmacokinetics of loxapine following inhalation of a thermally generated aerosol in healthy volunteers. <i>Journal of Clinical Pharmacology</i> , 2010 , 50, 169-79	2.9	45
83	The neurocircuitry of fear, stress, and anxiety disorders. <i>Neuropsychopharmacology</i> , 2010 , 35, 169-91	8.7	1372
82	Electroanalytical characteristics of antipsychotic drug ziprasidone and its determination in pharmaceuticals and serum samples on solid electrodes. <i>Talanta</i> , 2010 , 82, 286-95	6.2	54
81	Personalized medicine: the impact on chemistry. <i>Therapeutic Delivery</i> , 2010 , 1, 651-65	3.8	6

80	Pharmacotherapy of bipolar disorder in children and adolescents: recent progress. <i>CNS Drugs</i> , 2010 , 24, 575-93	6.7	22
79	Strategies for successful clinical management of schizophrenia with ziprasidone. <i>Expert Opinion on Pharmacotherapy</i> , 2010 , 11, 2199-220	4	15
78	Consider the underlying illness when treating acute agitation in paediatric patients. <i>Drugs and Therapy Perspectives</i> , 2011 , 27, 14-17	1.5	
77	Pharmacologic management of acutely agitated pediatric patients. <i>Paediatric Drugs</i> , 2011 , 13, 1-10	4.2	28
76	Bipolare affektive Störungen. 2011 , 1665-1700		
75	Guidelines for screening and monitoring of cardiometabolic risk in schizophrenia: systematic evaluation. <i>British Journal of Psychiatry</i> , 2011 , 199, 99-105	5.4	142
74	Educating and training the next generations of traumatologists: Development of cultural competencies.. <i>Psychological Trauma: Theory, Research, Practice, and Policy</i> , 2011 , 3, 258-265	7.8	16
73	Seasonality in depressive and anxiety symptoms among primary care patients and in patients with depressive and anxiety disorders; results from the Netherlands Study of Depression and Anxiety. <i>BMC Psychiatry</i> , 2011 , 11, 198	4.2	27
72	The illness and everyday living: close interplay of psychopathological syndromes and psychosocial functioning in chronic schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2011 , 261, 85-93	5.1	32
71	Circadian rhythms, melatonin and depression. <i>Current Pharmaceutical Design</i> , 2011 , 17, 1459-70	3.3	69
70	Transition from ziprasidone im to oral formulation in agitated patients with acute exacerbation of schizophrenia: an open trial. <i>Pharmacopsychiatry</i> , 2011 , 44, 173-8	2	4
69	Measuring psychosocial outcomes in schizophrenia patients. <i>Current Opinion in Psychiatry</i> , 2011 , 24, 91-94.9		45
68	Pattern of acute induction of Homer1a gene is preserved after chronic treatment with first- and second-generation antipsychotics: effect of short-term drug discontinuation and comparison with Homer1a-interacting genes. <i>Journal of Psychopharmacology</i> , 2011 , 25, 875-87	4.6	34
67	Cytogenetic effects of valproic acid and ziprasidone in human lymphocyte cultures. <i>Neuropsychobiology</i> , 2011 , 64, 219-23	4	5
66	Bipolar Disorder in 10–17 Year Old Patients: Treatment Options and Cautions. <i>Clinical Medicine Reviews in Therapeutics</i> , 2011 , 3, 259-278		
65	Oral ziprasidone in the treatment of patients with bipolar disorders: a critical review. <i>Expert Review of Clinical Pharmacology</i> , 2011 , 4, 163-79	3.8	3
64	Mood stabilizers for patients with bipolar disorder: the state of the art. <i>Expert Review of Neurotherapeutics</i> , 2011 , 11, 85-99	4.3	30
63	A UK panel consensus on the initiation of aripiprazole for the treatment of bipolar mania. <i>International Journal of Psychiatry in Clinical Practice</i> , 2012 , 16, 244-58	2.4	3

62	Two 6-week, randomized, double-blind, placebo-controlled studies of ziprasidone in outpatients with bipolar I depression: did baseline characteristics impact trial outcome?. <i>Journal of Clinical Psychopharmacology</i> , 2012 , 32, 470-8	1.7	45
61	Comparison of self- and clinician ratings of Personal and Social Performance in patients with schizophrenia: the role of insight. <i>Psychopathology</i> , 2012 , 45, 109-16	3.4	14
60	Inhaled loxapine for rapid treatment of agitation in schizophrenia and bipolar disorder: an update. <i>Neuropsychiatry</i> , 2012 , 2, 253-260	1.8	1
59	Atypical antipsychotic-induced mania/hypomania: a review of recent case reports and clinical studies. <i>International Journal of Psychiatry in Clinical Practice</i> , 2012 , 16, 2-7	2.4	18
58	Solid organ transplantation: technical progress meets human dignity: a review of the literature considering elderly patients health related quality of life following transplantation. <i>Ageing Research Reviews</i> , 2012 , 11, 181-7	12	12
57	Can transcranial brain-targeted bright light treatment via ear canals be effective in relieving symptoms in seasonal affective disorder? A pilot study. <i>Medical Hypotheses</i> , 2012 , 78, 511-5	3.8	14
56	Modeling interneuron dysfunction in schizophrenia. <i>Developmental Neuroscience</i> , 2012 , 34, 152-8	2.2	12
55	Ziprasidone attenuates brain injury after focal cerebral ischemia induced by middle cerebral artery occlusion in rats. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2012 , 39, 69-74	5.5	8
54	Current Schizophrenia. 2012 ,		0
53	Aripiprazole: a review of its use in the management of schizophrenia in adults. <i>CNS Drugs</i> , 2012 , 26, 155-83	3	49
52	Mood disorders, circadian rhythms, melatonin and melatonin agonists. <i>Journal of Central Nervous System Disease</i> , 2012 , 4, 15-26	4.4	17
51	In vitro and in vivo characterization of amorphous, nanocrystalline, and crystalline ziprasidone formulations. <i>International Journal of Pharmaceutics</i> , 2012 , 428, 8-17	6.5	29
50	Molecular communication nanonetworks inside human body. <i>Nano Communication Networks</i> , 2012 , 3, 19-35	2.9	57
49	Cognitive impairment associated with schizophrenia: a review of the humanistic burden. <i>Advances in Therapy</i> , 2012 , 29, 148-62	4.1	46
48	Administration of mesenchymal stem cells and ziprasidone enhanced amelioration of ischemic brain damage in rats. <i>Molecules and Cells</i> , 2013 , 36, 534-41	3.5	19
47	Ethnic differences in seasonal affective disorder and associated factors among five immigrant groups in Norway. <i>Journal of Affective Disorders</i> , 2013 , 151, 237-42	6.6	14
46	The long-term clinical benefit and effectiveness of switching to once-daily quetiapine extended release in patients with schizophrenia. <i>Current Medical Research and Opinion</i> , 2013 , 29, 227-39	2.5	7
45	Ziprasidone ameliorates anxiety-like behaviors in a rat model of PTSD and up-regulates neurogenesis in the hippocampus and hippocampus-derived neural stem cells. <i>Behavioural Brain Research</i> , 2013 , 244, 1-8	3.4	26

44	Metabolic effects of adjunctive aripiprazole in clozapine-treated patients with schizophrenia. <i>Acta Psychiatrica Scandinavica</i> , 2013 , 127, 217-26	6.5	40
43	Chemotherapy-induced pseudobulbar affect: a novel case. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2013 , 25, E11-3	2.7	3
42	Off-licence prescribing and regulation in psychiatry: current challenges require a new model of governance. <i>Therapeutic Advances in Psychopharmacology</i> , 2013 , 3, 233-43	4.9	11
41	Intramuscular ziprasidone versus haloperidol for managing agitation in Chinese patients with schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2013 , 33, 178-85	1.7	21
40	The epidemiology and pathophysiology of pseudobulbar affect and its association with neurodegeneration. <i>Degenerative Neurological and Neuromuscular Disease</i> , 2013 , 3, 23-31	5.4	8
39	Behavioral Emergencies for the Emergency Physician. 206-210		
38	Ziprasidone in Pediatric Bipolar Disorder: A 6-Week, Open-Label Comparison of Rapid vs. Slow Dose Titration. <i>Journal of Depression & Anxiety</i> , 2013 , 02,	0	
37	Electroretinographic modifications induced by agomelatine: a novel avenue to the understanding of the claimed antidepressant effect of the drug?. <i>Neuropsychiatric Disease and Treatment</i> , 2014 , 10, 907-14	3.1	11
36	Therapieziel soziale Funktionsfähigkeit. <i>Der Neurologe Und Psychiater</i> , 2014 , 15, 46-54	0	0
35	Revisions and refinements of the diagnosis of schizophrenia in DSM-5.. <i>Clinical Psychology: Science and Practice</i> , 2014 , 21, 236-244	3.7	5
34	Correlation between the Personal and Social Performance scale (PSP) and the Positive and Negative Syndrome Scale (PANSS) in a Greek sample of patients with schizophrenia. <i>BMC Psychiatry</i> , 2014 , 14, 197	4.2	21
33	Psychomotor symptoms and treatment outcomes of ziprasidone monotherapy in patients with major depressive disorder: a 12-week, randomized, double-blind, placebo-controlled, sequential parallel comparison trial. <i>International Clinical Psychopharmacology</i> , 2014 , 29, 332-8	2.2	4
32	Serotonin syndrome after the use of tramadol and ziprasidone in a patient with a deep brain stimulator for Parkinson disease. <i>American Journal of Therapeutics</i> , 2014 , 21, e97-9	1	9
31	Review of Dextromethorphan 20 mg/Quinidine 10 mg (NUEDEXTA(®)) for Pseudobulbar Affect. <i>Neurology and Therapy</i> , 2014 , 3, 15-28	4.6	26
30	Long-term trajectories of positive and negative symptoms in first episode psychosis: A 10year follow-up study in the OPUS cohort. <i>Schizophrenia Research</i> , 2015 , 168, 84-91	3.6	90
29	[Living and health conditions of elderly people over 80]. <i>Revista Gaucha De Enfermagem / EENFURGS</i> , 2015 , 36, 42-8	0.5	6
28	How Light Resets Circadian Clocks. 2015 , 243-297		3
27	Pharmacoscintigraphy studies to assess the feasibility of a controlled release formulation of ziprasidone. <i>Journal of Controlled Release</i> , 2015 , 213, 10-17	11.7	11

26	Determinants of postnatal depression in rural ghana: findings from the don population based cohort study. <i>Depression and Anxiety</i> , 2015 , 32, 108-19	8.4	40
25	Efficacy of ziprasidone monotherapy in patients with anxious depression: a 12-week, randomized, double-blind, placebo-controlled, sequential-parallel comparison trial. <i>Journal of Psychiatric Research</i> , 2015 , 62, 56-61	5.2	5
24	Bright-light intervention induces a dose-dependent increase in striatal response to risk in healthy volunteers. <i>NeuroImage</i> , 2016 , 139, 37-43	7.9	5
23	Seasonal and meteorological associations with depressive symptoms in older adults: A geo-epidemiological study. <i>Journal of Affective Disorders</i> , 2016 , 191, 172-9	6.6	34
22	Seasonal difference in brain serotonin transporter binding predicts symptom severity in patients with seasonal affective disorder. <i>Brain</i> , 2016 , 139, 1605-14	11.2	41
21	Seasonal variations in mood and behavior associate with common chronic diseases and symptoms in a population-based study. <i>Psychiatry Research</i> , 2016 , 238, 181-188	9.9	12
20	Use of Compounded Dextromethorphan-Quinidine Suspension for Pseudobulbar Affect in Hospice Patients. <i>Journal of Palliative Medicine</i> , 2017 , 20, 294-297	2.2	0
19	Psychopharmacological Approaches to Aggression and Violence in Adults with Severe Mental Illness: What Works? What Works Best?. 2017 , 1-15		
18	Unresolved Issues for Utilization of Atypical Antipsychotics in Schizophrenia: Antipsychotic Polypharmacy and Metabolic Syndrome. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	44
17	Herbal medicines in the treatment of psychiatric disorders: 10-year updated review. <i>Phytotherapy Research</i> , 2018 , 32, 1147-1162	6.7	72
16	Pharmacotherapy for the pseudobulbar affect in individuals who have sustained a traumatic brain injury: a systematic review protocol. <i>JBI Database of Systematic Reviews and Implementation Reports</i> , 2018 , 16, 1739-1757	1.6	2
15	Reliability, validity and validation of the CNS emotional lability scale for pseudobulbar affect on multiple sclerosis in Turkish patients. <i>Journal of Theoretical Social Psychology</i> , 2018 , 28, 306-313	1.2	1
14	Melanopsin Retinal Ganglion Cells and Pupil: Clinical Implications for Neuro-Ophthalmology. <i>Frontiers in Neurology</i> , 2018 , 9, 1047	4.1	25
13	Acetylene black-chitosan mediated electro-oxidation of serotonin and melatonin: an efficient platform for simultaneous voltammetric sensing. <i>Ionics</i> , 2019 , 25, 2337-2349	2.7	15
12	Clinical Cases in Psychiatry: Integrating Translational Neuroscience Approaches. 2019 ,		1
11	Social Capital as a Mediator through the Effect of Education on Depression and Obesity among the Elderly in China. <i>International Journal of Environmental Research and Public Health</i> , 2020 , 17,	4.6	5
10	Daily and Seasonal Variation in Light Exposure among the Old Order Amish. <i>International Journal of Environmental Research and Public Health</i> , 2020 , 17,	4.6	3
9	A strategy for treating pseudobulbar affect. <i>Neurology Psychiatry and Brain Research</i> , 2020 , 37, 52	2.1	

- 8 Randomized Double-blind Trial of Intramuscular Droperidol, Ziprasidone, and Lorazepam for Acute Undifferentiated Agitation in the Emergency Department. *Academic Emergency Medicine*, **2021**, 28, 421-434 3-1 7
- 7 Efficacy of Carbamazepine and Its Derivatives in the Treatment of Bipolar Disorder. *Medicina (Lithuania)*, **2021**, 57, 3-1 2
- 6 Evaluation and medication therapy for treatment resistance in schizophrenia. *Medical Psychiatry*, **2009**, 185-200
- 5 References. 165-193
- 4 Effect of initial ziprasidone dose on treatment outcome of korean patients with acute manic or mixed episodes. *Psychiatry Investigation*, **2011**, 8, 207-13 3-1
- 3 Organization of Care and Treatment. **2013**, 69-156
- 2 Bipolare affektive Störungen. **2015**, 1-36
- 1 Bipolare affektive Störungen. **2017**, 1819-1854 0